Amplia Therapeutics Ltd (ASX:ATX) CEO and managing director Dr Chris Burns has had a long career in drug development, including discovering only the second Australian drug to receive US Food and Drug Administration (FDA) approval. He has plenty of advice to share for Australian-based researchers and domestically developed biotech assets. Proactive's Susanna Nelson chats to him about the current state of clinical research and commercial drug development in Australia.
You can follow the Proactive After Market podcast on Spotify Music and Apple Podcasts to stay up to date with all the latest episodes.